Article
Beyond the comprehensive metabolic panel: Using biomarkers to help identify underlying drivers of liver disease
Topics: News & Trends
Sign up for the latest testing guidance
Join our email list for the most up-to-date testing recommendations and noteworthy clinical innovations that impact your patients.
Updated dyslipidemia guidance on earlier lipid risk assessment
The 2026 American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines emphasize earlier screening, lower target lipid goals, and the adoption of the revised Predicting Risk of Cardiovascular Disease EVENTs (PREVENT™) calculator.
Find Provider Insights in your LinkedIn feed
Clinical best practices are ever-evolving as science advances. Follow Quest for Healthcare Professionals for new guidelines and tests that impact how you make diagnostic decisions in the primary care setting.
Contact your Quest representative
If you or your practice need additional support selecting the right test at the right time for your patients, Quest is here to help.
- Site map
- Privacy Notices
- Terms
- Contact us
- Language assistance / non-discrimination
- Asistencia de idiomas / Aviso de no discriminación
- 語言協助 / 不歧視通知
- Accessibility
-
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.